Jakub Tolar, MD, PhD

Dean, Medical School

Jakub Tolar

Contact Info

tolar003@umn.edu

Office Phone 612-626-4949

Office Address:
C607 Mayo

Mailing Address:
420 Delaware Street SE
MMC 293
Minneapolis, MN 55455

Administrative Assistant Name
Nou Ka Yang

Administrative Phone
612-626-4990

Administrative Email
yang6652@umn.edu

Dean, Medical School

Interim Vice President for Health Sciences, Academic Health Center

Distinguished McKnight Professor, Department of Pediatrics

Director, Stem Cell Institute

Edmund Wallace Tulloch and Anna Marie Tulloch Chair, Stem Cell Biology, Genetics and Genomics

Professor, Microbiology, Immunology and Cancer Biology (MICaB) Ph.D. Graduate Program


Pediatric Blood and Marrow Transplant Physician


Medical School, Charles University

Residency in Pediatrics, University of Minnesota

Fellowship in Pediatrics and Hematology/Oncology and Blood and Marrow Transplantation, University of Minnesota

PhD, Molecular, Cellular, Developmental Biology and Genetics, University of Minnesota

Summary

Originally from the Czech Republic, Jakub Tolar received his medical education in Prague at the Charles University. In 1992, he came to the University of Minnesota, where he completed his PhD in Molecular, Cellular & Developmental Biology and Genetics. 

Dr. Tolar is Dean of the Medical School; a Distinguished McKnight Professor in the Department of Pediatrics, Blood and Marrow Transplantation; Director of the Stem Cell Institute; and the Edmund Wallace Tulloch & Anna Marie Tulloch Chair in Stem Cell Biology, Genetics & Genomics. He is a member of the graduate faculty of the Microbiology, Immunology and Cancer Biology (MICaB) Program, the Molecular, Cellular, and Developmental Biology and Genetics (MCDB&G) Program, and the Stem Cell Biology (SCB) Program.

He has a clinical practice through the University of Minnesota Masonic Children's Hospital, and his interests include educating and mentoring new physicians.

Dr. Tolar is active in many professional societies, and is a strong advocate for cooperation and communication within the clinical and research communities.

Expertise

Epidermolysis bullosa, Fanconi anemia, dyskeratosis congenita, Hurler syndrome (MPS), gene therapy, genome editing

Awards & Recognition

  • Distinguished McKnight Professorship
  • Best Doctors in America®, 2015, 2017-2018
  • Mpls.St.Paul Magazine "Top Doctor," 2012-2017
  • Innovator in Translational Research Award, 2014
  • Rare Disease Research Hall of Fame (NORD), 2013
  • Leadership in Healthcare: Change Agent (MN Business Magazine, 2013
  • Edmund Wallace Tulloch and Anna Marie Tulloch Chair in Stem Cell Biology, Genetics and Genomics, 2013-present
  • Albert D. and Eva J. Corniea Chair, 2011-2013
  • Butterfly Award, Children’s Cancer Research Fund, 2009
  • Elected to Society of Pediatric Research, 2005
  • University Pediatrics Foundation Scholar, 2005
  • NIH/NICHD Child Health Research Scholar, 2003-2005
  • Margaret Kendrick Hostetter MD Award for Research in Pediatric Subspecialty Training (1st place Fellow Research Symposium), 2003
  • American Society of Clinical Oncology Young Investigator Award, 2003
  • Amy Strelzer Manasevit Scholars Program Bone Marrow Transplant Award, 2002
  • MD summa cum laude and Academic Achievement Award of the Chancellor, 1st Medical School, Charles University, 1990

Professional Associations

  • Attending Physician at the University of Minnesota Masonic Children’s Hospital

Languages

  • Czech

Research

Research Summary/Interests

Dr. Tolar's research focuses on finding new ways of treating children with lethal diseases - cancer, inborn errors of metabolism, and devastating genetic disorders - using stem cell transplantation. He is also looking for safer and more effective methods of repairing and using a patient's own cells in diseases such as epidermolysis bullosa, mucopolysaccharidosis type I (Hurler syndrome), Fanconi anemia, and dyskeratosis congenita. Additional research interests include: reducing the negative effects of stem cell transplantation (such as using mesenchymal stromal cells for graft-versus-host disease), creation and use of induced pluripotent stem cells, gene therapy using gene addition (with viral vectors and trasposons), or gene editing (with synthetic nucleases to repair genes).

Publications

A Selection of Recent Publications

  • Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Gabriel R, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, Schmidt M, Hippen KL, Miller JS, Scharenberg AM, Tolar J, Blazar BR. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9 and megaTAL nucleases. Mol Ther. 2016 Mar;24(3):570-81. http://dx.doi.org/10.1038/mt.2015.197
  • Modiano JF, Lindborg BA, McElmurry RT, Lewellen M, Forster CL, Zamora EA, Schaack J, Bellgrau D, O'Brien TD, Tolar J. 2015. Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment. Cancer Immunol Immunother. 64(11):1449-60
  • Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, Starker CG, Wagner JE, Joung JK, Voytas DF, von Kalle C, Schmidt M, Blazar BR, Tolar J. Fanconi anemia gene editing by the CRISPR/Cas9 system. Hum Gene Ther. 2015 Feb;26(2):114-26. http://dx.doi.org/10.1089/hum.2014.111
  • Modiano JF, Lindborg BA, McElmurry RT, Lewellen M, Forster CL, Zamora EA, Schaack J, Bellgrau D, O'Brien TD, Tolar J. 2015. Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment. Cancer Immunol Immunother. 64(11):1449-60
  • Tolar J, McGrath JA, Xia L, Riddle M, Lees CJ, Eide C, Keene DR, Liu L, Osborn MJ, Lund TC, Blazar BR, Wagner JE. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2014 May;134(5):1246-54. http://dx.doi.org/10.1038/jid.2013.523.
  • Tolar J, Wagner JE. Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix. Lancet. 2013 Oct 5;382(9899):1214-23. http://dx.doi.org/10.1016/s0140-6736(13)61897-8
  • Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, DeFeo AP, Gabriel R, Schmidt M, von Kalle C, Carlson DF, Maeder ML, Joung JK, Wagner JE, Voytas DF, Blazar BR, Tolar J. TALEN-based gene correction for epidermolysis bullosa. Mol Ther. 2013 Jun;21(6):1151-9. Commentary “Enzymes fix disease genes” in Nature, vol 497, May 2, 2013. http://dx.doi.org/10.1038/mt.2013.56

Click here to see a complete list of Dr. Tolar’s work which has been published by academic and research journals.

Clinical

Clinics

Journey Clinic - Center for Pediatric Blood and Marrow Transplantation

Board Certifications

  • Pediatric Hematology/Oncology

Clinical Interests

Blood and marrow transplantation; Gene therapy for correction of genetic diseases

Media

Video

Video

Meet The Team: Jakub Tolar, M.D., Ph.D., U of M Pediatric Blood and Marrow Transplant Center